anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a hair dye having excellent dyeing performance and safety by using a ylidoid glycoside or its aglycon as an active component. CONSTITUTION:The objective agent contains, as an active component, 0.01-20% ylidoid glycoside extracted and separated from a plant of family Rubiaceae, Euphorbiaceae, Valerianaceae, etc., or an aglycon which is a hydrolyzed product of the glycoside. As necessary, the components are properly compounded with dissolution assistant, stabilizer, pH modifier, preservative, etc., to obtain the objective hair dye. A hair cosmetic can be prepared by adding a cosmetic carrier to the hair dye. The product is a vegetable-originated hair dye having low side effects such as skin stimulation, rush and hair damage. The dyed hair has high color fastness and single dyeing operation gives dyed hair resistant to bleaching over a long period. Ylidoid glycoside or its aglycon reacts with compounds having functional groups existing in hair (e.g. amino group and hydroxyl group) and forms pigments having various color tones.
Adults

For normal healthy adults, the individual maximum recommended dose of lidocaine HCl with epinephrine should not exceed 7 mg/kg (3.5 mg/lb) of body weight, and in general it is recommended that the maximum total dose not exceed 500 mg. When used without epinephrine the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight, and in general it is recommended that the maximum total dose does not exceed 300 mg. For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes. When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia.

The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total. One half of the total dose is usually administered to each side. Inject slowly, five minutes between sides (see also discussion of paracervical block in PRECAUTIONS).

For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.

Children

It is difficult to recommend a maximum dose of any drug for children, since this varies as a function of age and weight. For children over 3 years of age who have a normal lean body mass and normal body development, the maximum dose is determined by the child’s age and weight. For example, in a child of 5 years weighing 50 lbs the dose of lidocaine HCl should not exceed 75 to 100 mg (1.5 to 2 mg/lb). The use of even more dilute solutions (i.e., 0.25 to 0.5%) and total dosages not to exceed 3 mg/kg (1.4 mg/lb) are recommended for induction of intravenous regional anesthesia in children.

In order to guard against systemic toxicity, the lowest effective concentration and lowest effective dose should be used at all times. In some cases it will be necessary to dilute available concentrations with 0.9% sodium chloride injection in order to obtain the required final concentration.

NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. The Injection is not to be used if its color is pinkish or darker than slightly yellow or if it contains a precipitate.

*Dose determined by number of dermatomes to be anesthetized (2 to 3 mL/dermatome). 

THE ABOVE SUGGESTED CONCENTRATIONS AND VOLUMES SERVE ONLY AS A GUIDE. OTHER VOLUMES AND CONCENTRATIONS MAY BE USED PROVIDED THE TOTAL MAXIMUM RECOMMENDED DOSE IS NOT EXCEEDED.
Compounds having a prolonged adrenocorticotropic hormonal activity consist of a sparingly soluble complex of a pharmaceutically suitable salt, hydroxide or oxide of a metal retarding the resorption of protein hormones and a peptide, having adrenal cortex stimulating activity, consisting of the amino-acid sequence of at least the first 19 and not more than the first 31 amine acid residues from the N-terminal end of an ACTH molecule as obtained from mammals. Suitable metals are Zu; Cu; Ni; Co; and Fe; and they are used in quantities of 1 to 20 mgs. of metal per 100 U.S.P. units of peptide. Preferred salts are phosphate, chloride, acetate and sulphate. Particular peptides mentioned are synthetic 19, 20, and 24 amino-acid residue peptides and 26 and 31 residue peptides prepared by enzymic degradation of a natural mammalian ACTH molecule.  The term "peptide" includes functional derivatives thereof, such as amides, hydrazides, esters, and acid or alkali addition salts.  Also, the invention relates to injectable compositions of the complexes suspended in an aqueous injectable vehicle; such compositions have a pH of 6.0 to 8.0, and preferably also contain a preservative, such as a phenol benzyl alcohol, or a p-hydroxy benzoic acid ester; a solute such as sodium chloride to make the solution isotonic with body fluids; a buffer, and a phosphorus oxy-acid, or its salt, or a derivative of such an acid (e.g. nucleoside phosphate; phosphoserine; or creatine phosphate), which substances have stabilizing properties.  The complex may either be used in suspension, if a sparingly soluble metal salt is employed, or may, if a soluble salt is used, be in the form of a solution.  The complexes are prepared by mixing aqueous solutions or suspensions of the salt, oxide or hydroxide, and the hormone.  The injectible preparation may also take the form of an aqueous solution of salt and protein outside the stated pH range of 6.0 to 8.0 (e.g. pH 4.0) which, on injection, forms the sparingly soluble complex at the pH of the tissue fluids.
Disclosed are a computing apparatus, a computer-readable medium and a method that enable a user to use subjective inputs to alter settings of a wearable automatic drug delivery system. A user input device is presented on a graphical user interface that enables input of a subjective insulin need parameter. In response to receiving the input, the processor may modify a subjective coefficient value. A specific factor useable by an automatic insulin delivery algorithm is set based on the subjective coefficient value. Physiological condition data related to the user and the set specific factor may be used to determine a dosage of insulin to be delivered to the user based on the collected physiological condition data of the user. The processor may cause the determined dosage of insulin to be delivered to the user based on an output of the automatic insulin delivery algorithm.
Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
Takayasu's arteritis is a rare inflammatory disease that affects the aorta and its branches. The disease is much more common in females than in males, and disease onset typically occurs between the ages of 15 and 30. People with this disease often experience general discomfort, fatigue, fever, night sweats, weight loss, and joint pain. In the late stages of the disease, weak arterial walls may lead to aneurysms. Many patients do not exhibit any visible symptoms until this point, however. Because many people with Takayasu's arteritis do not have overt disease symptoms, the assessment of disease activity is difficult. Laboratory tests can help, but are often unreliable. Novel approaches to assessing disease activity are urgently needed to enhance and facilitate research on Takayasu's arteritis. This study will determine the effectiveness of combination positron emission tomography/computed axial tomography (PET/CT) in assessing disease activity in people with Takayasu's arteritis.

Participants in this study will enroll while their disease is active. The first PET/CT scan will take place upon study entry, while there is active disease. Participants will have a second PET/CT scan 3 months later, and a third scan 3 months after that if there is still active disease present. Participants will have a maximum of 3 scans unless a scan needs to be repeated because of technical failures, though this does not often happen. If there is no active disease at the time of the second scan, a third scan will not be done. All PET/CT scans will be scheduled within 10 days of participants' routine MRI scans. This study will not require any follow-up visits.
Evekeo has a high potential for abuse and misuse. The use of Evekeo exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Amphetamine sulfate can be diverted for non-medical use into illicit channels or distribution (see DRUG ABUSE and DEPENDENCE). Misuse and abuse of CNS stimulants, including Evekeo, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. 

Before prescribing Evekeo, assess each patient's risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give Evekeo to anyone else. Throughout Evekeo treatment, reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
The two major determining factors for Alzheimer's disease (AD) are genetics and lifestyle. Alleles of the apolipoprotein E (APOE) gene play important roles in the development of late-onset AD, with APOEɛ4 increasing risk, APOEɛ3 being neutral, and APOEɛ2 reducing risk. Several modifiable lifestyle factors have been studied in terms of how they can modify the risk of AD. Among these factors are dietary pattern, nutritional supplements such as omega-3 fatty acids, and B vitamins, physical exercise, and obesity, and vitamin D. The Western diet increases risk of AD, while dietary patterns such as the Mediterranean and vegetarian/vegan diets reduce risk. Foods associated with reduced risk include coffee, fruits and vegetables, whole grains and legumes, and fish, while meat and ultraprocessed foods are associated with increased risk, especially when they lead to obesity. In multi-country ecological studies, the amount of meat in the national diet has the highest correlation with risk of AD. The history of research regarding dietary patterns on risk of AD is emphasized in this review. The risk of AD can be modified starting at least by mid-life. People with greater genetic risk for AD would benefit more by choosing lifestyle factors to reduce and/or delay incidence of AD.
Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy linked to high-risk human papillomavirus (HPV) infection, which develops from precursor lesions like low-grade squamous intraepithelial lesions and high-grade squamous intraepithelial lesions (HGSILs). ASCC incidence varies across populations and poses increased risk for people living with HIV. Our investigation focused on transcriptomic and metatranscriptomic changes from squamous intraepithelial lesions to ASCC. Metatranscriptomic analysis highlighted specific bacterial species (e.g., Fusobacterium nucleatum, Bacteroides fragilis) more prevalent in ASCC than precancerous lesions. These species correlated with gene-encoding enzymes (Acca, glyQ, eno, pgk, por) and oncoproteins (FadA, dnaK), presenting potential diagnostic or treatment markers. Unsupervised transcriptomic analysis identified distinct sample clusters reflecting histological diagnosis, immune infiltrate, HIV/HPV status, and pathway activities, recapitulating anal cancer progression's natural history. Our study unveiled molecular mechanisms in anal cancer progression, aiding in stratifying HGSIL cases based on low or high risk of progression to malignancy.
Coronary heart disease is the leading cause of death and disability in the US, accounting for about one-third of all deaths in subjects over age 35.

With the development of newer Magnetic Resonance Imaging (MRI) techniques, such as faster pulse sequences and parallel imaging, cardiac MRI has become a routine tool for the evaluation and detection of myocardial ischemic disease. First pass myocardial perfusion (FPMP) using MRI is increasingly being used to assess ischemic heart disease. MRI offers the advantages of spatial resolution sufficient to differentiate between subendocardial and subepicardial perfusion; shorter examination time and also lack of ionizing radiation. Left ventricle cine gradient echo imaging can be used to assess regional ventricular function. Left ventricular myocardial viability can also be easily assessed at the same time in order to determine the amount of viable left ventricular myocardium and the percentage of irreversibly scarred myocardium by delayed enhanced images. Viability imaging is usually added to the perfusion protocol to increase specificity by allowing detection of fixed perfusion defects, which represent scar. The ultimate cardiac MRI protocol would be to combine both of these imaging strategies with a reliable and accurate coronary Magnetic Resonance Angiography(MRA) technique, such that obstructive coronary artery disease could be evaluated comprehensively at the same time. If all of these techniques can be combined together in a single study, it may be feasible to finally achieve a "one stop shop" for cardiac Magnetic Resonance Imaging.
Losartan is widely used in the treatment of chronic kidney disease (CKD) and has achieved good clinical efficacy, but its exact mechanism is not clear. We performed high-throughput sequencing (HTS) technology to screen the potential target of losartan in treating CKD. According to the HTS results, we found that the tumor necrosis factor (TNF) signal pathway was enriched. Therefore, we conducted in vivo and in vitro experiments to verify it. We found that TNF signal pathway was activated in both unilateral ureteral obstruction (UUO) rats and human proximal renal tubular epithelial cells (HK-2) treated with transforming growth factor-β1 (TGF-β1), while losartan can significantly inhibit TNF signal pathway as well as the expression of fibrosis related genes (such as COL-1, α-SMA and Vimentin). These data suggest that losartan may ameliorate renal fibrosis through modulating the TNF pathway.
In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents. Agranulocytosis (including fatal cases) has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue ziprasidone at the first sign of decline in WBC in the absence of other causative factors.

Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm3) should discontinue ziprasidone and have their WBC followed until recovery.
<P>PROBLEM TO BE SOLVED: To provide a bathing agent producing a new form assuming a shaved ice state or a sherbet state and original bathing effects in a bathing agent used as a powdery material, a liquid material or a solid material.  <P>SOLUTION: The bathing agent is composed of at least a liquid material 1 and a particulate material 5 and the liquid material is selected from an oily ingredient 2, a surfactant 3, a high polymer 4 and water 9. The oily ingredient is selected from oils and fats 21, waxes 22, hydrocarbons 23, higher alcohols 24 and esters 25. The surfactant is selected from a nonionic surfactant 31, an anionic surfactant 32, a cationic surfactant 33 and an amphoteric surfactant 34 and the high polymer is selected from xanthan gum 4a, tara gum 4b, etc. The particulate material is a particulate salt material 6 which is selected from a seawater particulate salt 6a obtained from seawater E, a deep water particulate salt 6b prepared from deep sea water F, a natural particulate salt 6c prepared from rock salt or a salt lake and inorganic salts 6d composed of chemical ingredients.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The study is multi-site, randomized, double-blind, sham-controlled study of the safety and efficacy of multi-dose Provant therapy to evaluate neuronal and vascular response in the treatment of subjects with painful peripheral diabetic neuropathy. Subjects will be randomized in a 2:1 ratio to receive therapy with an active device or an identical inactive sham device. Subjects will treat at home twice daily for 60 days after which they will return to the clinic for final evaluations. Subjects will be evaluated at the research center for a Baseline/Enrollment visit and again at Day 61 where assessments for safety, concomitant medications, Sympathetic Skin Response (SSR), Nerve Conduction Velocity (NCV), Skin Perfusion Pressures (SPP), and Skin Biopsy will be completed. Subjects will be contacted via telephone at Day 14, Day 28 and Day 42 to assess adherence, safety, and concomitant medications. Subjects will also complete a Response to Study Device form which will capture their daily pain score.
The utility model relates to a disposable shaped treatment crown, which is aimed to provide a shaped crown that can fix treatment medicine on the teeth surface and prevent the saliva from dissolving and diluting the medicine, and enable the medicine effect to act on the disease part for a long time, thus improving the treatment effect. The utility model is characterized in that firstly  the invention can be adhered with the water suction materials vertically and in half side, along a strip aluminum (tin) membrane (1) (with a length of a row of teeth or according to the instance of the diseased teeth, with a width of two times of the height of the teeth); secondly the invention  can add the medicine (3) (e.g. drug liquid, drug plaster, etc.) into the water suction materials. When being used, the aluminum (tin) membrane should be folded into V shape along the vertical, and then be covered on the teeth (the face with the water suction materials should be close to the disease part of the teeth). The inside and outside of the aluminum (tin) membrane should be gently pressed so as to make the aluminum (tin) membrane close to the teeth surface, forming the treatment crown in according with the shape of the teeth. The product is with simple structure, low cost, relatively good treatment effect, disposable, convenient and healthy, thus the disposable shaped treatment crown is easy to be spread broadly.
The invention provides a monoclonal antibody ZJU11-03 for resisting H1N1 influenza virus hemagglutinin protein and application thereof. Immunizing a BALB/C mouse by purified H1N1 influenza virus hemagglutinin protein, collecting B lymphocytes of the sensitized BALB/C mouse and mouse myeloma cells for fusion, judging positive clones by using an enzyme-linked immunosorbent assay, establishing a hybridoma cell line ZJU11-03 secreting an anti-H1N 1 influenza virus hemagglutinin protein monoclonal antibody, amplifying and culturing the positive cells, injecting the amplified cells into the abdominal cavity of the mouse of the same strain for induction to generate antibody-containing ascites, and collecting the ascites and carrying out affinity purification on the ascites and the antibody to obtain the anti-H1N 1 influenza virus hemagglutinin protein monoclonal antibody ZJU 11-03. The heavy chain variable region amino acid sequence of the antibody is shown in SEQ ID No.2, and the light chain variable region amino acid sequence is shown in SEQ ID No. 4. The monoclonal antibody is further subjected to physicochemical property analysis and functional identification, and the monoclonal antibody is established to be used as a medicament for treating the H1N1 subtype seasonal influenza virus infection. The invention provides an effective tool for treating the seasonal influenza virus infection of H1N1, and can be popularized and used for combined application with other medicines and other researches.
BACKGROUND: Perforated marginal ulcers (PMUs) are a rare but known complication of bariatric surgery. Management typically involves prompt surgical intervention, but limited data exists on non-operative approaches. This study reviews published data on non-operative management of PMUs and presents a case series of patients who were managed non-operatively. Our hypothesis is that certain patients with signs of perforation can be successfully managed non-operatively with close observation.
METHODS: We completed a systematic review searching PubMed, Embase, Web of Science, Cochrane, and clinicaltrials.gov. Ultimately 3 studies described the presentation and non-operative management of 5 patients. Additionally, we prospectively collected data from our institution on all patients who presented between Dec. 2022 and Dec. 2023 with PMUs confirmed on imaging and managed non-operatively.
RESULTS: In our literature review, three patients had Roux-en-Y gastric bypass (RYGB), while two had one anastomosis gastric bypass. One patient required surgery two days after admission. Another underwent elective conversion surgery weeks later for a non-healing ulcer. Two received endoscopic interventions. One patient recovered with nil-per-os (NPO) status, and intravenous proton pump inhibitor (PPI) treatment. The patients in our case series presented with normal vital signs, an average of 30 months after RYGB, and with CT scan signs of perforation. None of these patients required surgical or endoscopic intervention.
CONCLUSION: In conclusion, while perforated marginal ulcers have traditionally been considered a surgical emergency, some patients can be successfully treated with non-operative management. More research is needed to identify the clinical presentation features, comorbidities, and imaging findings of this group.
The invention belongs to the field of biomedical engineering, and particularly relates to a tumor affinity peptide for a human epidermal growth factor receptor 2 and application thereof, wherein the tumor affinity peptide comprises 6 sequences such as Leu-Arg-Leu-Ser-Gly-Gly-Hyp-Gln and the like. Pharmacodynamic experiments prove that the polypeptide can be used for cancer diagnosis and treatment. These high affinity polypeptides can specifically bind to a variety of tumor cells. The targeting peptide with high affinity can be used for optical imaging and nuclear medicine imaging of malignant tumors. The high-affinity polypeptide monomer, polypeptide dimer or polypeptide polymer directly or indirectly coupled fluorescent dye can be used as a tumor specific targeting molecular probe, is expected to achieve the effect of accurately positioning tumor boundaries, can bring real-time performance to image navigation before and during operation, and has the advantage of improving the operation accuracy. The series of polypeptide monomers, dimers or polymers can also be coupled with radionuclides to detect malignant tumors in real time in vivo so as to achieve the purpose of disease diagnosis or treatment.
Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.